Cargando…
Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?
Scientific societies have provided guidelines to reduce PSA-specific harms. We studied the potential non-compliance of PSA testing with current guidelines in general practice. A cross-sectional study of a random sample of 1291 patients with a PSA test was performed between January and April 2018 in...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234229/ https://www.ncbi.nlm.nih.gov/pubmed/34208627 http://dx.doi.org/10.3390/jcm10122650 |
_version_ | 1783714035370295296 |
---|---|
author | Bernal-Soriano, Mari Carmen Parker, Lucy Anne López-Garrigós, Maite Hernández-Aguado, Ildefonso Gómez-Pérez, Luis Caballero-Romeu, Juan-Pablo Pastor-Valero, María García, Nuria Alfayate-Guerra, Rocío Lumbreras, Blanca |
author_facet | Bernal-Soriano, Mari Carmen Parker, Lucy Anne López-Garrigós, Maite Hernández-Aguado, Ildefonso Gómez-Pérez, Luis Caballero-Romeu, Juan-Pablo Pastor-Valero, María García, Nuria Alfayate-Guerra, Rocío Lumbreras, Blanca |
author_sort | Bernal-Soriano, Mari Carmen |
collection | PubMed |
description | Scientific societies have provided guidelines to reduce PSA-specific harms. We studied the potential non-compliance of PSA testing with current guidelines in general practice. A cross-sectional study of a random sample of 1291 patients with a PSA test was performed between January and April 2018 in primary health care. Patients with a previous prostate cancer diagnosis or those who were being followed-up for previous high PSA values were excluded. Two independent researchers classified whether each test was potentially non-compliant with recommendations. We estimated frequencies of potentially non-compliant PSA determinations and calculated prevalence ratios (PR) to assess their relationship with possible explanatory variables. A total of 66% (95% CI: 62–69%) of PSA requests in asymptomatic patients were potentially non-compliant with the current guideline. This was associated with having a previous diagnosis of neoplasm (PR adjusted by age and life expectancy: 1.18; 95% CI: 1.02–1.37) as well as being a current consumer of tobacco, alcohol, or other drugs (PR: 0.80; 95% CI: 0.67–0.97). Real world data shows that patients are still frequently exposed to overdiagnosis risk with a PSA potentially non-compliant with recommendations. Patients diagnosed with another neoplasm or non-consumers of toxic substances were more exposed, probably due to increased contact with doctors or health-seeking behaviour. |
format | Online Article Text |
id | pubmed-8234229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82342292021-06-27 Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? Bernal-Soriano, Mari Carmen Parker, Lucy Anne López-Garrigós, Maite Hernández-Aguado, Ildefonso Gómez-Pérez, Luis Caballero-Romeu, Juan-Pablo Pastor-Valero, María García, Nuria Alfayate-Guerra, Rocío Lumbreras, Blanca J Clin Med Article Scientific societies have provided guidelines to reduce PSA-specific harms. We studied the potential non-compliance of PSA testing with current guidelines in general practice. A cross-sectional study of a random sample of 1291 patients with a PSA test was performed between January and April 2018 in primary health care. Patients with a previous prostate cancer diagnosis or those who were being followed-up for previous high PSA values were excluded. Two independent researchers classified whether each test was potentially non-compliant with recommendations. We estimated frequencies of potentially non-compliant PSA determinations and calculated prevalence ratios (PR) to assess their relationship with possible explanatory variables. A total of 66% (95% CI: 62–69%) of PSA requests in asymptomatic patients were potentially non-compliant with the current guideline. This was associated with having a previous diagnosis of neoplasm (PR adjusted by age and life expectancy: 1.18; 95% CI: 1.02–1.37) as well as being a current consumer of tobacco, alcohol, or other drugs (PR: 0.80; 95% CI: 0.67–0.97). Real world data shows that patients are still frequently exposed to overdiagnosis risk with a PSA potentially non-compliant with recommendations. Patients diagnosed with another neoplasm or non-consumers of toxic substances were more exposed, probably due to increased contact with doctors or health-seeking behaviour. MDPI 2021-06-16 /pmc/articles/PMC8234229/ /pubmed/34208627 http://dx.doi.org/10.3390/jcm10122650 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bernal-Soriano, Mari Carmen Parker, Lucy Anne López-Garrigós, Maite Hernández-Aguado, Ildefonso Gómez-Pérez, Luis Caballero-Romeu, Juan-Pablo Pastor-Valero, María García, Nuria Alfayate-Guerra, Rocío Lumbreras, Blanca Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
title | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
title_full | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
title_fullStr | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
title_full_unstemmed | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
title_short | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
title_sort | do the prostate-specific antigen (psa) tests that are ordered in clinical practice adhere to the pertinent guidelines? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234229/ https://www.ncbi.nlm.nih.gov/pubmed/34208627 http://dx.doi.org/10.3390/jcm10122650 |
work_keys_str_mv | AT bernalsorianomaricarmen dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT parkerlucyanne dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT lopezgarrigosmaite dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT hernandezaguadoildefonso dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT gomezperezluis dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT caballeroromeujuanpablo dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT pastorvaleromaria dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT garcianuria dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT alfayateguerrarocio dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT lumbrerasblanca dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines |